NasdaqGM:XNCRBiotechs
Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story?
Xencor recently announced that Phase 1 results for XmAb819, its bispecific antibody for advanced clear cell renal cell carcinoma, were accepted for an oral presentation at the 2026 ESMO Congress, highlighting expansion-cohort data that informed the recommended Phase 3 dose.
This recognition at a major oncology meeting, along with plans to begin a pivotal XmAb819 monotherapy study in 2027, underscores how Xencor’s antibody engineering platform is extending beyond inflammatory and autoimmune...